Novartis’ antibody drug ianalumab passes two Phase 3 studies in Sjögren’s diseasenews2025-08-11T10:50:04+00:00August 11th, 2025|Endpoints News|
FDA restricts use of bluebird’s gene therapy due to increased cancer risknews2025-08-08T18:41:13+00:00August 8th, 2025|Endpoints News|
HHS official tasked with MAHA relations fired following mRNA cutsnews2025-08-08T18:15:12+00:00August 8th, 2025|Endpoints News|
FDA approves Boehringer’s pill for HER2-mutated lung cancernews2025-08-08T18:06:51+00:00August 8th, 2025|Endpoints News|
Gilead cuts several mid- and early-stage programsnews2025-08-08T15:10:27+00:00August 8th, 2025|Endpoints News|
CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlementnews2025-08-08T14:05:04+00:00August 8th, 2025|Endpoints News|
Gilead says it ‘hit the ground running’ on its long-acting HIV shot launchnews2025-08-08T01:57:40+00:00August 8th, 2025|Endpoints News|
UPDATED: Two courts reject arguments against IRA in win for governmentnews2025-08-07T18:55:49+00:00August 7th, 2025|Endpoints News|
New FDA program aims to speed up construction of US manufacturing sites news2025-08-07T15:45:47+00:00August 7th, 2025|Endpoints News|
